RxDoctor Payments Data

Howard Herrmann, MD

Interventional Cardiology · Philadelphia, PANPI 1679503783

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $178,286 of the $258,645 with a category attached, or 68.9%. Medtronic accounts for 88.7% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $90,144, 3.8 times the $23,584 reported in 2019. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$258,645in general payments, 2019–2025

Across 412 payments — averaging $627.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$229K
  • Edwards Lifesciences$15K
  • Abbott$8K
  • Shockwave Medical, Inc$3K
  • Biosense Webster, Inc.$1K
  • Boston Scientific$357
  • plus $1K from 11 others
$2,024,712in research payments, 2019–2025

Across 291 payments — averaging $6957.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.1M
  • Medtronic$585K
  • Shockwave Medical, Inc$113K
  • Abbott$64K
  • Boston Scientific$59K
  • Bayer$57K
  • plus $20K from 1 others

What the payments were for

  • Consulting fees$40,00015%
  • Speaking & faculty fees$178,28669%
  • Grants$890%
  • Travel & lodging$27,81611%
  • Food & beverage$12,2305%
  • Education$2250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,645 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,991
Medicare patients
400
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$17,151
Rosuvastatin Calcium16$345
Metoprolol Succinate26$316
Furosemide12$157
Losartan Potassium11$92

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →